Holen Sie sich die Stockscreener-App
2.99
6.41%
0.18
Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of “Buy” by Analysts - Defense World
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Raymond James - Defense World
Raymond James Begins Coverage on Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Jefferies initiates Buy rating on Inozyme Pharma stock, highlights potential of INZ-701 - Investing.com
Affinity Asset Advisors, LLC Increases Stake in Inozyme Pharma I - GuruFocus.com
Inozyme Pharma stock hits 52-week low at $2.53 amid market challenges - Investing.com Canada
Eventide Asset Management LLC Purchases 198,216 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Inozyme Pharma to Present at Piper Sandler Healthcare Conference | INZY Stock News - StockTitan
Inozyme Pharma stock hits 52-week low at $2.6 amid market challenges - Investing.com Canada
Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St
Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com
Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com
Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan
Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World
Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World
FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World
Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat
Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India
Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks
Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):